The International Liver Congress (ILC) 2018, the 53rd annual meeting of the European Association for the Study of the Liver (EASL), was held this year in Paris, France, and was attended by 9,669 delegates from 121 countries. The field of hepatology is undergoing dramatic changes, with a major increase in metabolic liver diseases and liver cancer worldwide, highly effective drugs to cure hepatitis C now available, and multiple novel treatment concepts for rare liver diseases and hepatitis B emerging.
During the opening ceremony, the ILC 2018 Honorary President, Tilman Sauerbruch, reminded the audience of the huge clinical and scientific advances that have been made in hepatology during the course of his illustrious career. He highlighted that, for example, survival after the first liver transplantations performed by Thomas Starzl in 1963 was just 0–23 days, compared with 1-year survival rates of 85% now, 55 years later. In other areas in the same time period, all viral causes of hepatitis were identified. However, despite these real advances in hepatology, many challenges remain…
The ILC2018 Congress Report was supported by grants from: Abbvie, Alexion Pharma GmbH, Boehringer Ingelheim, Gilead Sciences Europe Ltd, MSD and Pfizer.